文献速递脊柱关节炎

银屑病关节炎中TNF、IL-17与IL-23(p19)抑制剂的耐受性与比较有效性:一项目标试验模拟研究

Tolerability and comparative effectiveness of TNF, IL-17 and IL-23(p19) inhibitors in psoriatic arthritis: a target trial emulation study.
PubMed 文献 · Rheumatology (Oxford) · 2024-01-01

基于PIPA前瞻性队列模拟目标试验,比较TNFi、IL-17i与IL-23(p19)i在银屑病关节炎中的药物留存与疗效。共纳入109例(TNFi 75例、IL-17i 26例、IL-23(p19)i 8例),12个月内倾向评分调整后HR分别为1.36(95%CI 0.59-3.14)和0.56(95%CI 0.10-3.24)。结论为组水平上无决定性差异,三类药物可能同等有效。

要点

  • 12个月药物留存:IL-17i与IL-23(p19)i对比TNFi的调整HR分别为1.36与0.56,置信区间均跨1。
  • TNFi与IL-17i在12个月后的应答率和临床结局变化上效果相当。
  • IL-23(p19)i整体趋势表现更好,但该组仅8例。

核心结论

  • 组水平上,三类药物在12个月药物留存和临床结局方面未观察到决定性差异。
  • TNFi、IL-17i和IL-23(p19)i可能均同等有效,作者提倡进一步研究个体化治疗策略。

研究设计与样本

  • 基于Parker研究所银屑病关节炎队列(PIPA队列)的前瞻性队列观察数据,模拟目标试验进行比较有效性分析。
  • 所有患者在基线和4个月、12个月随访时接受访谈和临床检查方案。
  • 主要终点为自基线起至12个月的药物留存,采用比例风险模型估计风险比,并用倾向评分调整以去混杂并模拟随机治疗分配。
  • 意向监测人群共109例,基线起始TNFi 75例、IL-17i 26例、IL-23(p19)i 8例。

主要发现

  • 倾向评分调整模型中,IL-17i对比TNFi的HR为1.36(95%CI 0.59-3.14)。
  • 倾向评分调整模型中,IL-23(p19)i对比TNFi的HR为0.56(95%CI 0.10-3.24)。
  • TNFi与IL-17i在12个月后的应答率和临床结局变化上效果相当。
  • IL-23(p19)i整体趋势表现更好。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To compare the tolerability and effectiveness of two different classes of biological DMARDs [IL-17 and IL-23(p19) inhibitors, IL-17i and IL-23(p19)i] relative to TNF inhibitors (TNFi) regarding the drug survival rates and treatment outcomes in patients with PsA. METHODS: We emulated a target trial on comparative effectiveness using observational data from a prospective cohort study based on the Parker Institute's PsA cohort (the PIPA cohort). All patients underwent interview and a clinical examination programme at baseline and at follow-up visits at 4 and 12 months. The primary endpoint, drug survival, was assessed up to 12 months from baseline. We estimated hazard ratios from proportional hazards model and used propensity score adjustment in an attempt to deconfound and emulate a random treatment assignment. RESULTS: We included a total of 109 patients in the intention-to-monitor population at baseline initiating either TNFi (75 patients), IL-17i (26 patients) or IL-23(19)i (8 patients). Hazard ratios in the propensity adjusted model comparing IL-17i and IL-23(p19)i with TNFi were 1.36 (95% CI 0.59-3.14) and 0.56 (95% CI 0.10-3.24), respectively. TNFi and IL-17i had comparable effects regarding response rates and changes in clinical outcomes after 12 months, whereas IL-23(p19)i tended to perform better overall. CONCLUSION: No decisive differences between drugs were observed at group level regarding drug survival and clinical outcomes after 12 months. TNFi, IL-17i and IL-23(p19)i may all be considered equally effective in the treatment of patients with PsA, advocating for investigating more in personalized treatment strategies.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Stisen ZR, Nielsen SM, Skougaard M, et al. Tolerability and comparative effectiveness of TNF, IL-17 and IL-23(p19) inhibitors in psoriatic arthritis: a target trial emulation study. Rheumatology (Oxford). 2024. PMID: 37713434. doi:10.1093/rheumatology/kead488

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。